Vaxcyte Stock Jumps 30.7% After Positive VAX-31 Pneumococcal Vaccine Data
Vaxcyte shares surged 30.70% after positive Phase 2 data for VAX-31, highlighting the volatility of clinical-stage biotech catalysts.
Amgen Price Target Raised to $380 as Sjögren’s Trial Strengthens Pipeline Case
Truist raised Amgen’s target to $380 after positive Phase 3 dazodalibep results strengthened the company’s pipeline narrative.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
BridgeBio Maintains Buy Rating After Cardiac Data From Phase 3 FORTIFY Study
Canaccord reiterated its Buy rating on BridgeBio Pharma after exploratory cardiac data from the Phase 3 FORTIFY study of…
AbbVie Adds Two FDA Breakthrough Designations as Temab-A Builds Pipeline Momentum
AbbVie’s Temab-A earned two FDA breakthrough designations, adding an oncology catalyst alongside JUVMO approval and broa…
Lipocine Stock Jumps 30% on Health Canada Approval for TLANDO
LPCN’s 30% jump adds regulatory, commercial and clinical catalysts to a biotech trading setup focused on potential follo…
Vaxcyte Stock Jumps 30.7% on Positive VAX-31 Pneumococcal Vaccine Data
Vaxcyte’s $PCVX stock jumped 30.70% after positive VAX-31 data, putting vaccine developers back in the spotlight ahead o…
ArriVent BioPharma Stock Plunges 63% After Lung Cancer Drug Misses Phase 3 Endpoint
ArriVent BioPharma shares fell 63% after its Phase 3 FURVENT trial missed its primary endpoint, highlighting binary biot…
Option Care Health Surges 34% as McKesson and CD&R Agree to $5.8 Billion Takeover
Option Care Health jumped 34% after McKesson and CD&R agreed to a $5.8 billion takeover, highlighting ongoing US healthc…
ArriVent’s AVBP Plunges 60% After Lung Cancer Trial Misses Primary Endpoint
ArriVent shares plunged 60% after its lung-cancer trial missed the primary endpoint, despite dose-dependent response rat…
BridgeBio’s $BBIO Gains FDA Priority Review for Oral Infigratinib in Children With Achondroplasia
BridgeBio’s NDA for oral infigratinib received FDA acceptance and Priority Review, creating a closely watched regulatory…
Cenovus to Acquire Athabasca Oil in $5.7 Billion Cash-and-Stock Deal
Cenovus will acquire Athabasca Oil in a $5.7 billion cash-and-stock transaction, marking a major step in Canadian oil sa…